What is receptor imaging in nuclear medicine?
Receptor imaging in nuclear medicine refers to the use of radiopharmaceuticals that bind specifically to cellular receptors, allowing in vivo visualisation of receptor expression. Rather than demonstrating perfusion or metabolism alone, receptor imaging reveals the presence, density, and distribution of specific molecular targets within tissues.
Receptor imaging visualises tissues based on specific ligand–receptor binding, allowing in vivo assessment of molecular target expression.
It is a form of molecular imaging that exploits ligand–receptor binding to generate contrast. Uptake reflects receptor biology rather than purely blood flow or anatomical structure.
Understanding the physics
Receptor imaging depends on specific and reversible molecular binding. A radiopharmaceutical designed for receptor imaging contains a targeting ligand with high affinity for a particular receptor. After intravenous administration, the compound circulates and encounters tissues throughout the body. Where the corresponding receptor is expressed, the ligand binds according to classical receptor kinetics.
The degree of uptake depends primarily on receptor density and binding affinity. Tissues with high receptor expression accumulate more tracer because a greater proportion of ligand becomes bound. This is fundamentally different from perfusion-based tracers, where uptake is governed mainly by blood flow.
Binding kinetics also influence image quality. If receptor binding is strong and internalisation occurs, the tracer may become trapped within cells, increasing retention and improving target-to-background ratio. Conversely, low affinity or rapid dissociation may reduce visible uptake.
Specific activity plays an important role in receptor imaging. If the preparation contains significant non-radioactive carrier, those molecules compete for receptor binding sites without contributing to the detected signal. High specific activity maximises the proportion of receptor-bound ligand that is radioactive, improving sensitivity.
Because receptor imaging reflects molecular biology, uptake patterns can vary with disease state. Tumours often overexpress certain receptors, allowing selective visualisation. In this way, receptor imaging provides information beyond structural imaging.
Where this matters clinically
Receptor imaging is central to modern oncologic imaging and theranostics. It enables identification of receptor-positive tumours, selection of patients for targeted radionuclide therapy, and monitoring of treatment response.
It represents a transition from functional imaging to true molecular imaging, where the imaging signal directly reflects receptor biology.